Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959567 | 0.89 | MTNR1B (0.52) | MTNR1BOPRM1OPRK1ALDH1A1KMT2A | |
| SCHEMBL11929926 | 0.85 | MTNR1B (0.47) | MTNR1BALDH1A1KMT2ANPSR1MEN1 | |
| SCHEMBL7214029 | 0.85 | MTNR1B (0.50) | MTNR1BOPRM1OPRK1ALDH1A1KMT2A | |
| SCHEMBL11934342 | 0.85 | OPRD1 (0.51) | MTNR1BOPRM1OPRK1ALDH1A1KMT2A | |
| SCHEMBL11934341 | 0.81 | MAPK1 (0.56) | MTNR1BOPRM1OPRK1ALDH1A1KMT2A | |
| SCHEMBL8125910 | 0.81 | MTNR1B (0.54) | MTNR1BOPRM1OPRK1ALDH1A1KMT2A | |
| SCHEMBL8125912 | 0.81 | MTNR1B (0.54) | MTNR1BOPRM1OPRK1ALDH1A1KMT2A | |
| SCHEMBL8125915 | 0.81 | MTNR1B (0.54) | MTNR1BOPRM1OPRK1ALDH1A1KMT2A | |
| SCHEMBL11934339 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL7344341 | 0.80 | ACE (0.61) | MTNR1BALDH1A1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | MTNR1B 885/4885OPRM1 545/4885OPRK1 655/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | MTNR1B 885/4885OPRM1 545/4885OPRK1 655/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | MTNR1B 885/4885OPRM1 545/4885OPRK1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.